Yahoo Finance 2 Top Growth Stocks to Buy Hand Over First in December
Despite the challenging economic environment, Global-e Online and Farfetch look positioned for a bright future.
Despite the challenging economic environment, Global-e Online and Farfetch look positioned for a bright future.
The March reading comes as investors have continued to scale back their expectations on when the Federal Reserve will cut interest rates in 2024, if at all.
BASF SE (PNK:BASFY) Q1 2024 Earnings Call Transcript April 25, 2024 Stefanie Wettberg: Good morning, ladies and gentlemen. On behalf of BASF, I would like to welcome you to our conference call on the First Quarter 2024 Results. Throughout today’s recorded presentation, all participants will be in listen-only mode. The presentation will be followed by […]
"It dawned on me: They were utterly terrified we were going to discover something very exciting and powerful about our supposedly naughty bodies."
HERCULES, Calif., April 26, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
Boca Raton, Florida, April 26, 2024 (GLOBE NEWSWIRE) -- IB Acquisition Corp. (NASDAQ: IBACU) (the “Company”) announced today that, on May 1, 2024, the Company’s units will no longer trade, and that the Company’s common stock and rights, which together comprise the units will commence trading separately. The common stock and rights will be listed on the Nasdaq Global Market and trade with the ticker symbols “IBAC” and “IBACR”, respectively. This is a mandatory and automatic separation, and no act
The retail market in the United States stands as one of the most prominent and dynamic in the world, boasting key players such as Walmart among its ranks. As per our data, total retail sales in the United States surged to an impressive US$ 7.24 trillion in 2023. This substantial figure underscores the robust consumer demand and market vitality within the nation.NEWARK, Del, April 26, 2024 (GLOBE NEWSWIRE) -- The FMCG logistics market is on its way to marking a valuation of US$ 117.1 billion in 2
ATLANTA, April 26, 2024--Manhattan wins Overall Innovation of the Year award by RetailTech Breakthrough for it's latest offering, Fulfillment Experience Insights.
LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica (NASDAQ: PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, takes center s
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the
WEST HOLLYWOOD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (NASDAQ: BNIX) (“Bannix” or the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced that on April 25, 2024, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) advising the Company that the Company did
TEMPE, Ariz., April 26, 2024--Align Technology, Inc. ("Align") (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $150 million of Align’s common stock through open market repurchases under Align’s $1.0 billion stock repurchase program that was approved by Al
Chicago, April 26, 2024 (GLOBE NEWSWIRE) -- Fill Finish Manufacturing market in terms of revenue was estimated to be worth $16.7 billion in 2024 and is poised to reach $25.7 billion by 2029, growing at a CAGR of 8.9% from 2024 to 2029 according to a latest report published by MarketsandMarkets™. The major factors driving the growth of this fill finish manufacturing market include the increasing demand for biopharmaceuticals and vaccines. Additionally, advancements in technology such as automated
WASHINGTON, April 26, 2024--Easterly Government Properties, Inc. (NYSE: DEA), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to U.S. Government agencies, announced today that its Board of Directors has approved a quarterly cash dividend of $0.265 per common share. The dividend will be payable on May 21, 2024 to shareholders of record on May 9, 2024.
CALGARY, Alberta, April 26, 2024 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSXV: CVX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company") a North American leading manufacturer and supplier of technologically advanced cellular concrete products today announced that it has executed $7.6 million in new contracts. A portion of the $7.6 million in new contracts is derived from two projects, with price tags greater than $1 million Canadian, and were previously included in Contracts in Process. These projects
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) produc
TORONTO, April 26, 2024 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (NEO: MLC) (“Mount Logan” or the “Company”) will release its financial results for the first quarter ended March 31, 2024 after market close on Thursday, May 9, 2024. The Company will host a conference call on Friday, May 10, 2024, at 11:00 a.m. Eastern Time to discuss these results. Shareholders, prospective shareholders, and analysts are welcome to listen to the conference call. To join the call, please use the dial-in inform
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) received notification that the Com
OSAKA, Japan & CAMBRIDGE, Mass., April 26, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when de
WEST PALM BEACH, FL, April 26, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. ("the Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, today announced its preliminary unaudited revenue for the first quarter ended March 31, 2024. Financial Highlights: ●First Quarter Revenues were $488,587, a 38% increase over the $352,799 reported in the first quarter of 2023. ●First Quarter Gross Profit was $2